Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. | Cost Effectiveness and Resource Allocation BioMed Central Open Access Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States Nicolas M Furiak1 Haya Ascher-Svanum 2 Robert W Klein1 Lee J Smolen1 Anthony H Lawson2 Robert R Conley3 and Steven D Culler4 Address 1Medical Decision Modeling Inc. Indianapolis IN USA 2Eli Lilly and Company Indianapolis IN USA 3Lilly USA LLC Indianapolis IN USA and 4Emory University Atlanta GA USA Email Nicolas M Furiak - nf@mdm-inc.com Haya Ascher-Svanum - haya@lilly.com RobertW Klein - rwk@mdm-inc.com Lee J Smolen - leesmolen@mdm-inc.com Anthony H Lawson - lawsonan@lilly.com Robert R Conley - rconley@lilly.com Steven D Culler - sculler@sph.emory.edu Corresponding author Published 7 April 2009 Received 27 June 2008 Cost Effectiveness and Resource Allocation 2009 7 4 doi 10.1186 1478-7547-7-4 Accepted 7 April 2009 This article is available from http www.resource-allocation.com content 7 1 4 2009 Furiak et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.Org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Schizophrenia is often a persistent and costly illness that requires continued treatment with antipsychotics. Differences among antipsychotics on efficacy safety tolerability adherence and cost have cost-effectiveness implications for treating schizophrenia. This study compares the cost-effectiveness of oral olanzapine oral risperidone at generic cost primary comparator quetiapine ziprasidone and aripiprazole in the treatment of patients with schizophrenia from the perspective of third-party payers in the U.S. health care system. Methods A I-year microsimulation economic decision model with quarterly cycles was developed to simulate the dynamic .
